View Press Releases
Inizio Biotech makes key leadership appointment to meet demand from emerging biotech
September 14, 2022
Inizio Biotech, a business unit of Inizio, and a single source for best-in-class biotech services from clinical development to commercialization, has appointed Jay Janus as Senior Account Director.
In his role, Jay will act as the primary point of contact for emerging biotech partners, providing strategic guidance and connecting them with the knowledge and expertise of the wider Inizio network at the right moments in their development journey.
He has extensive experience in consulting early phase companies in the clinical trial space with a vast array of experience in medical writing, biostatistics, clinical trial design and data management.
Commenting on his appointment, Jay said: ”Emerging biotech companies have become incredibly skilled at developing molecules and progressing trials, but their journey to market requires further expertise and guidance to realize the potential and value of each company and their assets.
“It’s this gap that Inizio Biotech fills - acting as a strategic thought partner with access to specialist resources across commercialization. Our clients can access as little or as much access as they need, when they need it, and that is what truly differentiates us. I am excited to join the company at a time when the industry continues to go from strength to strength.”
Inizio Biotech provides personalized solutions, coordinated through single strategic points of contact that are supported by over 10,000+ experts. This includes over 650 PhDs providing therapeutic area and modality expertise across the clinical development and commercialization journey.
Discussing the appointment, Global President of Inizio Biotech, Jason McKenna said: “Jay joins us at a key moment in Inizio Biotech’s journey. Emerging Biotech are increasingly looking to us to not only consult but rapidly build a highly personalized multidisciplinary team that can maximize the true value of their asset. I looking forward to the future success of our clients with Jay’s guidance by their side.”
Jay will be attending FierceBioTech Summit in Boston, MA Sept 19-20 2022, please reach out for a meeting here.
Find out more about Inizio Biotech and its service offerings here.
ENDS
For media inquiries, please contact:
Lara Lovenbury, Account Director, ramarketing: lara@ramarketingpr.com | +44 797 247 1903
Lucy MacLauchlan, Global Head of Marketing, Inizio: lucy.maclauchlan@inizio.health | +44 7917 264 626
About Inizio
Uniting the expertise and capabilities of Ashfield and Huntsworth, Inizio is a strategic partner for companies in health and life sciences. Connecting a full suite of advisory, medical, marketing, communications and patient and stakeholder engagement services across the lifecycle of a drug, Inizio supports its partners from initial assessment to loss of exclusivity.
Inizio has five specialist business units, each comprising best-in-class companies that provide the depth, breadth and scale to activate transformational change and reimagine health.
Inizio is backed by Clayton, Dubilier & Rice (CD&R). For more information visit: www.inizio.health
In his role, Jay will act as the primary point of contact for emerging biotech partners, providing strategic guidance and connecting them with the knowledge and expertise of the wider Inizio network at the right moments in their development journey.
He has extensive experience in consulting early phase companies in the clinical trial space with a vast array of experience in medical writing, biostatistics, clinical trial design and data management.
Commenting on his appointment, Jay said: ”Emerging biotech companies have become incredibly skilled at developing molecules and progressing trials, but their journey to market requires further expertise and guidance to realize the potential and value of each company and their assets.
“It’s this gap that Inizio Biotech fills - acting as a strategic thought partner with access to specialist resources across commercialization. Our clients can access as little or as much access as they need, when they need it, and that is what truly differentiates us. I am excited to join the company at a time when the industry continues to go from strength to strength.”
Inizio Biotech provides personalized solutions, coordinated through single strategic points of contact that are supported by over 10,000+ experts. This includes over 650 PhDs providing therapeutic area and modality expertise across the clinical development and commercialization journey.
Discussing the appointment, Global President of Inizio Biotech, Jason McKenna said: “Jay joins us at a key moment in Inizio Biotech’s journey. Emerging Biotech are increasingly looking to us to not only consult but rapidly build a highly personalized multidisciplinary team that can maximize the true value of their asset. I looking forward to the future success of our clients with Jay’s guidance by their side.”
Jay will be attending FierceBioTech Summit in Boston, MA Sept 19-20 2022, please reach out for a meeting here.
Find out more about Inizio Biotech and its service offerings here.
ENDS
For media inquiries, please contact:
Lara Lovenbury, Account Director, ramarketing: lara@ramarketingpr.com | +44 797 247 1903
Lucy MacLauchlan, Global Head of Marketing, Inizio: lucy.maclauchlan@inizio.health | +44 7917 264 626
About Inizio
Uniting the expertise and capabilities of Ashfield and Huntsworth, Inizio is a strategic partner for companies in health and life sciences. Connecting a full suite of advisory, medical, marketing, communications and patient and stakeholder engagement services across the lifecycle of a drug, Inizio supports its partners from initial assessment to loss of exclusivity.
Inizio has five specialist business units, each comprising best-in-class companies that provide the depth, breadth and scale to activate transformational change and reimagine health.
Inizio is backed by Clayton, Dubilier & Rice (CD&R). For more information visit: www.inizio.health